DNA nuclear ploidy determined by flow cytometry was evaluated from prostatic tissue in 64 patients with prostatic cancer who had undergone radical prostatectomy. DNA ploidy was compared to tumour stage, tumour grading (Gleason score), PSA. DNA ploidy pattern was diploid in 46% and aneuploid in 54% of the tumours. Tumours pathologically staged B acc. to AUS were aneuploid in 25%, those staged C in 59% and those staged D in 66.6%. Aneuploidy was found in 36% of the tumours with Gleason score between 2 and 4, in 63% between 5 and 7 and in 45% between 8 and 10. Mean preoperative seric PSA was 34.3 ng/ml in diploid tumours and 39.8 ng/ml in aneuploid neoplasms. Our results suggest no relationship between tumour stage, grade and preoperative PSA.
KossL.G.CzerniakB.HerzF.WertsoR.P.: Flow cytometric measurements of DNA and other cell components in human tumours: a critical appraisal. Human Pathology, 20: 528–548, 1989.
2.
JonesE.C.McNealJ.BruchovskyN.: DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumour volume, percentage Gleason grade 4 and 5, and lymph node metastases. Cancer, 66: 752–757, 1990.
3.
LundbergS.CarstensenJ.RundquistI.: DNA flow cytometry and histopathological grading of paraffin-embedded prostate biopsy specimens in a survival study. Cancer Res., 47: 1973–1977, 1987.
4.
RitchieA.W.: Relationship of DNA content to conventional prognostic factors in clinically localized carcinoma of the prostate. Br. J. Urol., 62: 245–260, 1988.
5.
WithmoreW.F.: Hormone therapy in prostatic cancer. Am. J. Med., 21: 697–706, 1956.
6.
GleasonD.F.MellingerG.T.: The Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for adenocarcinoma and combined histological grading and clinical staging. J. Urol., 111: 58–64, 1956.
7.
HedleyD.W.FriedlanderM.L.TaylorI.W.: Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry, 6: 327–333, 1956.
8.
DeitchA.D.StrandM.A.De Vere WriteR.W.: Deoxyribonucleic acid Flow cytometry of benign prostatic disease. J. Urol., 142: 759–761, 1989.
9.
EpsteinI.J.PizovG.SteimbergD.G.CarterB.H.PitcockR.ArmasA.O.PartinA.WalshC.P.: Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and gleason grade with pathological stage of radical prostatectomy. J. Urol., 148: 87–91, 1992.
10.
JonesE.C.McNealJ.BrukovskyN.De JongG.: DNA content in prostatic adenocarcinoma. A flowcytometry study of the predictive value of aneuploidy for tumour volume, percentage Gleason grade 4–5, and lymph node metastases. Cancer, 66: 752–757, 1990.
11.
LeeS.E.CurrinS.M.PaulsonD.F.WalterJ.P.: Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopatological grading as a predictor of clinical recurrence. J. Urol., 140: 769–774, 1988.
12.
NativO.WinklerH.Z.RazY.TherneauT.M.FarrowG.M.MyersR.P.ZinckeH.LieberM.M.: Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analisys. Mayo Clin. Proc., 64: 911–919, 1989.
13.
RitchieA.W.: Relationship of DNA content to conventional prognostic factors in clinically localised carcinoma of the prostate. Br. J. Urol., 62: 245–260, 1988.
14.
UICC(Union Internationale Contre le Cancer - 1978). TNM Classification of Malignant Tumours. Third edition Geneva: International Union against Cancer.
15.
WeaverL.D.BagwellC.B.HithcoxS.A. et coll.: Improved flow cytometric determination of proliferative activity (S- phase fraction) from paraffin-embedded tissue. A.J.C.P., 5: 576–584, 1990.
16.
TinariN.NatoliC.AngelucciD.TenagliaR.FiorentinoB.Di StefanoP.AmatettiC.ZezzaA.NicolaiM.IacobelliS.: DNA and S-Phase fraction analisis by flow cytometry in prostate cancer. Cancer 4, 71: 1289–1296, 1993.
17.
NemotoR.HattoriK.UchidaK.ShimazuiT.NishijimaY.KoisoK.HaradaM.: S-phase fraction of human prostate adenocarcinoma studied with in vivo bromodeoxyuridine labeling. Cancer, 66: 509–514, 1990.
18.
AbrahamssonP.A.AlumetsJ.FalkmerS. et coll.: Peptide hormone and serotonine immunoreactive tumour cells in carcinoma of prostate. Pathol. Res. Pract., 182: 298–307, 1987.
19.
FalkmerU.G.: Methodologic sources of errors in image and flow cytometric DNA assessments of the malignancy potential of prostatic Carcinoma. Human Pathol. 4, 23: 360–367, 1992.
20.
TribukaitB.: Dna flow cytometry in carcinoma of the prostate for diagnosis, prognosis and study of tumour biology. Acta Oncol., 30: 187–192, 1991.
21.
KleerE.Larson-KellerJ.J.ZinckeH. e OesterlingJ.E.: Ability of preoperative serum prostate specific antigen to predict pathologic stage and DNA ploidy: Influence of clinical stage and tumour grade. J. Urol., 147: 388A, 1992.
